Monika K. Krzyzanowska, MD, of Princess Margaret Cancer Centre, summarizes a session that she co-chaired on this key topic.
Allison Kurian, MD, of Stanford University School of Medicine, discusses pressing questions about the clinical utility and value of extended genomic testing and other forms of precision medicine.
Lawrence N. Shulman, MD, of the University of Pennsylvania, discusses his paper, which explores lessons learned from analyses of the National Cancer Data Base. (Abstract 173)
Joseph V. Simone, MD, of the Simone Consulting Company, reflects on the prospects for the future of safety and quality.
Craig Earle, MD, of Canada’s Institute for Clinical Evaluative Sciences, summarizes abstracts discussed in a ticketed session that he co-chaired on this key topic. (Abstracts 173, 174, 175)
Kerin B. Adelson, MD, of the Yale Cancer Center, discusses an electronic decision support tool to capture staging data. This information allows automated reports for clinical trial screening, outcomes analysis, quality comparisons, and reporting. (Abstract 151)
